Met Ö - Search Results

1

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.

Mortensen REJ, Holmström MO, Lisle TL, Hasselby JP, Willemoe GL, Met Ö, Marie Svane I, Johansen J, Nielsen DL, Chen IM, Andersen MH. Mortensen REJ, et al. Among authors: met o. J Immunother Cancer. 2023 Mar;11(3):e006432. doi: 10.1136/jitc-2022-006432. J Immunother Cancer. 2023. PMID: 36948507 Free PMC article. Clinical Trial.

2

In-chip fabrication of free-form 3D constructs for directed cell migration analysis.

Olsen MH, Hjortø GM, Hansen M, Met Ö, Svane IM, Larsen NB. Olsen MH, et al. Among authors: met o. Lab Chip. 2013 Dec 21;13(24):4800-9. doi: 10.1039/c3lc50930c. Lab Chip. 2013. PMID: 24153393

3

[Chimeric antigen receptor T-cell therapy].

Müller K, Ifversen M, Kielsen K, Petersen SL, Met Ö, Svane IM. Müller K, et al. Among authors: met o. Ugeskr Laeger. 2019 Oct 14;181(20A):V05190309. Ugeskr Laeger. 2019. PMID: 31610841 Free article. Review. Danish.

4

Cellular based cancer vaccines: type 1 polarization of dendritic cells.

Hansen M, Met Ö, Svane IM, Andersen MH. Hansen M, et al. Among authors: met o. Curr Med Chem. 2012;19(25):4239-46. doi: 10.2174/092986712802884213. Curr Med Chem. 2012. PMID: 22834814 Review.

5

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.

Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met Ö, Hölmich LR, Andersen RS, Hadrup SR, Andersen MH, thor Straten P, Svane IM. Ellebaek E, et al. Among authors: met o. J Transl Med. 2012 Aug 21;10:169. doi: 10.1186/1479-5876-10-169. J Transl Med. 2012. PMID: 22909342 Free PMC article.

6

Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy.

Hansen M, Hjortø GM, Donia M, Met Ö, Larsen NB, Andersen MH, thor Straten P, Svane IM. Hansen M, et al. Among authors: met o. Vaccine. 2013 Jan 11;31(4):639-46. doi: 10.1016/j.vaccine.2012.11.053. Epub 2012 Nov 29. Vaccine. 2013. PMID: 23200882

7

HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.

Munir S, Andersen GH, Met Ö, Donia M, Frøsig TM, Larsen SK, Klausen TW, Svane IM, Andersen MH. Munir S, et al. Among authors: met o. Cancer Res. 2013 Mar 15;73(6):1764-76. doi: 10.1158/0008-5472.CAN-12-3507. Epub 2013 Jan 17. Cancer Res. 2013. PMID: 23328583

8

Broadening the repertoire of melanoma-associated T-cell epitopes.

Frøsig TM, Lyngaa R, Met Ö, Larsen SK, Donia M, Svane IM, Thor Straten P, Hadrup SR. Frøsig TM, et al. Among authors: met o. Cancer Immunol Immunother. 2015 May;64(5):609-20. doi: 10.1007/s00262-015-1664-x. Epub 2015 Feb 18. Cancer Immunol Immunother. 2015. PMID: 25854582 Free PMC article.

9

Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer.

Hjortsø MD, Larsen SK, Kongsted P, Met Ö, Frøsig TM, Andersen GH, Ahmad SM, Svane IM, Becker JC, Straten PT, Andersen MH. Hjortsø MD, et al. Among authors: met o. Oncoimmunology. 2015 Jan 30;4(1):e968480. doi: 10.4161/21624011.2014.968480. eCollection 2015 Jan. Oncoimmunology. 2015. PMID: 25949861 Free PMC article.

10

Spontaneous presence of FOXO3-specific T cells in cancer patients.

Larsen SK, Ahmad SM, Idorn M, Met Ö, Martinenaite E, Svane IM, Straten PT, Andersen MH. Larsen SK, et al. Among authors: met o. Oncoimmunology. 2014 Nov 14;3(8):e953411. doi: 10.4161/21624011.2014.953411. eCollection 2014. Oncoimmunology. 2014. PMID: 25960934 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters